What is CorWave?
Headquartered in Clichy, France, CorWave is a medical technology firm dedicated to the engineering of next-generation cardiac assist devices. By leveraging unique hydrodynamic principles, the company is developing pumps that mimic the physiological flow of the human heart, potentially reducing the complications associated with traditional left ventricular assist devices (LVADs). As a key player in the cardiovascular health landscape, CorWave occupies a critical position at the intersection of bioengineering and clinical cardiology, focusing on improving patient outcomes for those suffering from severe heart failure. The company's evolution from its early-stage development to its current enterprise-level scaling reflects a disciplined approach to R&D and regulatory milestones.
How much funding has CorWave raised?
CorWave has raised a total of $86.7M across 3 funding rounds:
Series A
$4M
Series B
$17.1M
Series C
$65.6M
Series A (2013): $4M with participation from G�rard Hasco�t
Series B (2016): $17.1M led by Novo Seeds, Bpifrance, Sofinnova Partners, Seventure Partners, and Ysios Capital
Series C (2023): $65.6M supported by Seventure Partners, Bpifrance, EIC Fund, Novo Holdings, Sofinnova Partners, and Ysios Capital
Key Investors in CorWave
Sofinnova Partners
A leading European venture capital firm in life sciences, specializing in healthcare and sustainability with a hands-on approach to company building.
Bpifrance
A French public investment bank that supports companies at every stage of development through credit, guarantees, and equity financing.
Novo Holdings
A Danish private limited liability company wholly owned by the Novo Nordisk Foundation, focused on long-term value creation in life sciences.
What's next for CorWave?
Following the latest major strategic investment, CorWave is positioned to transition from intensive research and development into broader clinical validation and market preparation. The infusion of capital will likely be directed toward scaling manufacturing capabilities, advancing multi-center clinical trials, and navigating the complex regulatory pathways required for commercialization in global markets. As the company matures, the focus will shift toward establishing a sustainable commercial footprint, ensuring that its innovative cardiac assist solutions are integrated into standard clinical practice for heart failure management. The continued support from its syndicate of life science investors provides the necessary runway to achieve these long-term strategic goals.
See full CorWave company page
